2565-005X

S2565-005X2026000100005

10.24875/j.gamo.25000100

México

EE.UU

México

España

México

EE.UU

México

00 03 2026

25 1 29 65

2017 139

1056e-71e

2018 18

PROSPECT Working Group Collaborators

2020 75

664-73

2015 40

68-74

2019 74

663-73

2012 17

95-104

2013 2

1-3

2013 60

365-70

2015 63

307-8

2017 61

643-8

2016 63

553-5

2016 63

159-67

2020 9

247-53

2021 13

1-9

2021 31

32-49

2024 12

161-9

2023 2023

5668399

2014 13

124-33

2021

2005 78

12-8

1998 41

471-81

2000 7

276-80

2018 4.a ed

2024 8

zra.e040

2019 6

144-6

2016 10

223-8

2025 15

9032

2006 59

644-52

2025

1986 77

933-43

2013 40

367-73

2021 9

2025 23

Oncoplastía extrema

2022

2010 251

632-9

2017 12

2022 29

2221-30

2018 172

523-37

2020 27

2288-96

2025 14

2021 47

2272-85

1907 46

1-19

2017 318

918-26

2013 310

1455-61

2006 98

599-609

2023 9

1557-64

2014 384

164-72

2015 1

E19-24

2022 6

zrac022

2014 21

3330-5

2010 11

927-33

2014 15

1303-10

2022 29

5732-44

2024 390

1163-75

2024 159

1393-03

2025 392

1051-64

2022 109

1293-9

2021 187

647-55

2025 36

149-57

2020 38

3987-98

2024 391

1981-91

2019 380

617-28

2013 14

609-18

2015 33

258-64

2022 276

e553-62

2020 26

2838-48

2024 25

1222-30

1998 5

140-9

1992 28

1415-8

2023 69

281-9

2024 73

103671

2024 31

4527-39

2024 50

108472

2025 32

952-66

2021 156

2019 11

1758835919827714

2021 123

71-9

2024

67-71

2020 184

335-43

2010 97

1659-65

2021 123

846-53

2020 53

189-200

2021 19

2022 12

740

2020 4

CD013280

2012 129

1173-87

2025

2010 125

463-74

2011 18

3117-22

2023 101

187-97

2017 5

2017 139

395-405

2022 150

973-83

2021 21

271-7

2016 137

385-93

2007 119

1409-22

2017 44

345-59

2012 129

572-81

2021 47

2272-85

100

2007 59

235-42

101

2017 140

681-90

102

2019 2nd ed

245-75

103

2008 121

728-34

104

2019 33

240-6

105

2016 263

219-27

106

2023 152 4S 4S

69S-80S

107

2025 14

5004

108

2020 106

514-24

109

2021 19

77-102

110

National Cancer Institute

111

2017 24

375-97

112

2001 345

159-64

113

2010 11

CD002748

114

2017 377

1288-91

115

2023 11

2201-12

116

2017

117

2018 4

CD002748

118

2019 90

1-2

119

2020 29

960-73

120

2019

121

2024 196

104277

122

2018 171

607-60

123

2023 23

497

124

2015 26 Suppl 5 Suppl 5

152-68

125

2021 28

367-77

126

2024 42

74-9

127

2022 21

37-45

128

2024 27

7-14

129

2021 25

1-126

130

2019 10

131

2012 35

751-64

132

2023 59

2-7

133

2021 35

1197-204

134

Early Breast Cancer Trialists'Collaborative Group (EBCTCG)

2005 365

1687-717

135

2018 379

111-21

136

Early Breast Cancer Trialists'Collaborative Group (EBCTCG)

2012 379

432-44

137

2018 16

310-20

138

ESMO Guidelines Working Group

2011 22 Suppl 6 Suppl 6

vi12-24

139

Panel Members

2011 22

1736-47

140

2016 2

322-9

141

2021 21

239-46.e4

142

2007 4

CD004421

143

2008 26

44-53

144

2015 33

2353-60

145

2008 358

1663-71

146

2005 23

2676-85

147

2003 21

1431-9

148

Early Breast Cancer Trialists'Collaborative Group EBCTCG

2019 393

1440-52

149

2024 42

3077-82

150

2017 376

2147-59

151

2022 193

555-64

152

Early Breast Cancer Trialists'Collaborative Group

2011 378

771-84

153

2022 14

1898

154

2017 24

2989-98

155

2016 387

849-56

156

2024 208

577-87

157

2023 83

673-85

158

2013 381

805-16

159

2023 41

1370-5

160

2020 38

1293-303

161

2024 203

13-28

162

2023 24

77-90

163

2024 10

164

2024 390

1080-91

165

2022 40

1816-37

166

2019 30

1776-83

167

2019 46

19-24

168

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline Expert Panel

2024 42

2233-5

169

2016 16

1263-75

170

2008 13

620-30

171

2011 12

236-44

172

2014 32

3744-52

173

2017 17

61-74

174

2016 76 4 Suppl 4 Suppl

Abstract S5-04

175

2011 29

4491-7

176

2016 76 4 Suppl 4 Suppl

Abstract PD5-01

177

2013 14

741-8

178

2015 372

134-41

179

2017 377

122-31

180

2020 80 4 Suppl 4 Suppl

Abstract GS1-04

181

2024 42

3643-51

182

2016 17

367-77

183

2017 18

1688-700

184

2021 21

80-91.e7

185

2022

186

2021 385

2336-47

187

2021 22

476-88

188

2019 176

377-86

189

2011 17

6012-20

190

2024 9

1003443

191

2018 36

735-40

192

2024 8

zra.e040

193

2025 202

110591

194

2023 13

217-30

195

2024 14

112-32

196

2024 2024

6207762

197

2024 14

1337815

198

2025 80

10388

199

2023 41

3184-93

200

2024 44

201

2023 117

102556

202

2024 84 9 Suppl 9 Suppl

GS02-07

203

2023 41

2159-65

204

2024 36

98-106

205

2024 129

315-27

206

2025 31 12 Suppl 12 Suppl

GS2-03

207

2024 24

663-75

208

2022 112

437-44

209

2015 24 Suppl 2 Suppl 2

S73-7

210

2023 103

201-17

211

2017 24

2925-34

212

2016 23

3232-8

213

2018 36

1981-90

214

2021 39

1485-505

215

2011 125

145-56

216

Early Breast Cancer Trialists'Collaborative Group (EBCTCG)

2018 19

27-39

217

2021 185

441-51

218

2017 29

642-52

219

2019 31

480-5

220

2023 27

221

2022 17

167-75

222

2020 382

810-21

223

2021 32

1216-35

224

2003 14

414-20

225

2020 27

4702-10

226

2007 110

244-54

227

2005 23

5108-16

228

2021 7

1791-9

229

2022 62 Suppl 1 Suppl 1

S12-6

230

2025 392

249-57

231

2024 35

429-36

232

2022 40 23 23

2612-35

233

2020 21

3528

234

2020 52 6 6

235

2018 20

236

2018 210

1376-85

237

2025 43

1720-41

238

2024 24

1276

239

2017 284

365-71

240

2011 18

932-8

241

2022 48

1699-705

242

2024 13

7545

243

2024 49

101160

244

2025 202

110600

245

2024 24

301-9

246

2024 120

496-507

247

2024 384

25-46

248

2024 118

1422-34

249

2024 25

e73-83

250

2023 199

67-77

251

2023 15

2278

252

2023 15

690

253

2024 3

254

2024 47

580-4

255

2023 15

4515

256

2025 15

31-47

257

2024 28

586-90

258

2023 30

1151-63

259

2023 105

102513

260

2023 11

417

261

2024 10

1370-8

262

2023 23

407-19

263

2024 16